UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

Ultrasensitive ctDNA Detection in Advanced Renal Cell Carcinoma - Juan Ruiz-Bañobre

Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...
UroToday

Managing Low-Volume Metachronous Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
UroToday

Restricted Mean Survival Time Analysis of First-Line IO Combinations in Advanced RCC - Yudai Ishiyama

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
UroToday

Etiology of Hunner Lesions: Linking Immune Dysregulation and Chronic Inflammation in Interstitial Cystitis/Bladder Pain Syndrome.

Hunner lesions (HL) are distinctive ulcerative bladder lesions characterized by a central scar and surrounding erythema. Traditionally, HL has been used as a clinical diagnostic tool for a subset of ...
UroToday

TALAPRO-3 Trial Results for Talazoparib plus Enzalutamide in HRR-Mutant mHSPC - Neeraj Agarwal

Neeraj Agarwal discusses TALAPRO-3, a 599-patient phase 3 trial randomizing HRR-mutated metastatic hormone-sensitive prostate cancer patients to ADT plus enzalutamide plus talazoparib versus ADT plus ...
UroToday

Extracorporeal shock wave therapy in patients with chronic prostatitis/chronic pelvic pain syndrome and erectile dysfunction: a systematic review and meta-analysis.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) frequently coexists with erectile dysfunction (ED) and is associated with substantial impairment in quality of life (QoL). Although ...
UroToday

Outcomes in the Management of Complex Renal Cysts: Balancing Overtreatment, Cost, and Radiation Exposure "Presentation" - Helen Gao

At the World Congress of Endourology and Uro-Technology, Helen Gao reviews outcomes for 106 adults with Bosniak II through IV renal cysts managed between 2010 and 2024. Surgical intervention rates ...
UroToday

APCCC 2026: Can Genomics/Artificial Intelligence Help to Minimize Over- or Undertreatment?

(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a high-risk and locally advanced prostate cancer session and a presentation by Dr. Jason Efstathiou ...
UroToday

Pharmacology, efficacy and safety of different extracts of Serenoa repens in patients with lower urinary tract symptoms and benign prostatic hyperplasia: a narrative review.

Aim of this review is to evaluate the pharmacological efficacy and safety of Serenoa repens extracts in managing lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Using ...
UroToday

CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer - Anna Wilkins

Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHHiP radiotherapy fractionation trial in localized prostate cancer. The MMAI ...